Alnylam Pharmaceuticals
ALNY
ALNY
315 hedge funds and large institutions have $12.3B invested in Alnylam Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 98 increasing their positions, 98 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
0% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 98
2.23% less ownership
Funds ownership: 97.18% → 94.95% (-2.2%)
Holders
315
Holding in Top 10
12
Calls
$155M
Puts
$139M
Top Buyers
| 1 | +$107M | |
| 2 | +$53.8M | |
| 3 | +$34.6M | |
| 4 |
SPC
Slate Path Capital
New York
|
+$23M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$20.6M |
Top Sellers
| 1 | -$111M | |
| 2 | -$65.5M | |
| 3 | -$62.9M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$43.1M |
| 5 |
Goldman Sachs
New York
|
-$35.7M |